'Saxenda' continues to dominate weight-loss market
By Kim, Jin-Gu | translator Kim, Jung-Ju
23.06.07 06:00:00
가나다라
0
KRW 15.9 billion sales of Saxenda in Q1… 53% increase compared to the same period last year
Qsymia, 21% increase to KRW 7.7 billion... 'non-face-to-face treatment pilot project' a variable
Wegovy and Mounjaro's impending release... out of stock in the North American market
▲Product Photos of Saxenda (LT) and Qsymia (RT)
'Saxenda (Liraglutide)' is further strengthening its dominance in the obesity treatment market. In the first quarter, it recorded sales of KRW 15.9 billion, 53% increase from the previous year, more than doubling the gap with the runner-up product, 'Qsymia (Phentermine+Topiramate).'
However, it remains to be seen how much longer Saxenda's dominance will last, as release of promising products such as 'Wegovy (Semaglutide)' and 'Mounjaro (Tirzepatide)' are imminent in the obesity treatment market. The pharmaceutical industry predicts that the two products which have proven their marketability in the global market will be released in Korea as early as this year.
Saxenda grows 53%
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)